Item 8.01. Other Events.
On September 29, 2017, AveXis, Inc. (the Registrant) issued a press release to announce that the U.S. Food and Drug Administration has notified the Registrant that it may initiate its planned pivotal trial of AVXS-101 in spinal muscular atrophy (SMA) Type 1 using the intravenous formulation produced by the Registrants Good Manufacturing Practice commercial manufacturing process. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.